Stock Ratings / Health Care / IQV / dividends

INCY (84) MEDP (80) CRL (63) ICLR (71) ⌘ Pro Terminal →

IQVIA Holdings Inc. (IQV) Dividend Safety Gauge & 10-Year DRIP Compounder

$267.33 -2.81% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $265.47

IQVIA Holdings Inc. (IQV) carries a Roarable Rating of C (Hold) with 64/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 64/100 (C) historically posted market-perform odds over rolling 90-day windows (+1.1% avg 90D alpha vs SPY) →

ROARABLE C • HOLD / WATCH Cap $45.33B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on IQV Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is IQV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, IQVIA Holdings Inc. (NYSE: IQV) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 64/100 at a spot price of $267.33 (-2.81% 1D, market cap $45.33B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 18/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 13/20. Across 1016 tracked Health Care issuers, IQV ranks #132 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does IQV compare to INCY and MEDP in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), IQV carries a Roarable C (64/100 RQD), trailing P/E of 33.3x, gross margin of —, and ROIC of 9.4%. By comparison, INCY (Incyte Corp.) holds a A- grade (84/100 RQD, P/E 18.4x, ROIC 42.4%, cap $23.68B) and MEDP (Medpace Holdings Inc.) posts a B+ grade (80/100 RQD, P/E 42.0x, ROIC 27.9%, cap $18.95B). Among the 5-stock peer group, INCY leads on earnings multiple (18.4x) while INCY leads on capital efficiency (42.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for IQV?

▼

Per IQV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001478242), IQVIA Holdings Inc. generated $16.31B in revenue (+5.9% YoY), $1.36B in net income, and $1.92B in free cash flow against $29.94B in total assets and $13.88B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $265.46 (-0.70%)🧬 Cannibal Buyback (-1.52% YoY Shares)⚙️ Cash Engine: 13/20 (C) • 11.8% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 64/100 (C) historically posted market-perform odds over rolling 90-day windows (+1.1% avg 90D alpha vs SPY • 55.2% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE+2.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IQV)Realized 20D OHLCV Swing Band: ±6.8%

Deterministic 5-Pillar Attribution (64/100 Composite)

🔍 WHY IQV SCORES 64/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+18/20 pts (28% of score)

20D Institutional Volume Accumulation (±6.8% realized swing band)

▲ #2 Bullish Driver: Cash Engine Quality+13/20 pts (20% of score)

SEC XBRL FY 2025 (10-K): 11.8% FCF Margin ($1.92B FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Macro Regime Fit10/20 pts (-10 pt drag)

Macro rate sensitivity & RSI-14 (55.7) create a -10 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$260.68+2.8% Next Q

Q2 (-2Q)

Grade C$267.85+1.4% Next Q

Q3 (-1Q)

Grade C$271.55-1.6% Next Q

Current

Grade C$267.33+1.1% Hist 90D α

Trajectory: C (56) → C (64)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the IQV Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 64/100 (C) score, IQV faces multiple-compression risk if 33.3x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($266.69) or 200D SMA ($209.87) invalidates the momentum regime and cuts Target Base ($274.55) toward Bear Floor ($214.15).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $IQV• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “IQV Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 64%NO 36%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $307/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Cash-Flow & Quality Compounder Desk

Cash-Fortress Compounders: Auditing Free Cash Flow & Yield Safety in IQV & A-Rated Leaders

✓12-month Bull/Base/Bear fair-value walkthrough on IQV and its top sector peer
✓Top Roarable A-Rated cash compounders with verified executive & 13F accumulation
✓Includes nightly RQD rating-change & forensic signal email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

IQV // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +66.11%🛡️ HOLDING TREND SUPPORT

2026-11-02O $279.0H $279.0L $267.3C $267.3VOL 1.43M

RES: $333.3SUP: $265.1SMA50: $266.7SMA200: $209.9

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IQV Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IQV Butterfly Map → + Track IQV →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

25.7%/yr Implied 5Y Growth

vs. +5.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on IQV today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IQV. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for IQV today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IQV)

Health Care Rank #132 of 1016 ⚔️ INCY vs IQV Full Matrix →

1. Head-to-Head Health Care Peer Comparison (IQV vs. INCY, MEDP, CRL, ICLR)

Industry: Biotechnology: Commercial Physical & Biological Resarch (12 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, IQVIA Holdings Inc. (IQV) ranks #132 by composite RQD confidence (64/100, grade C) and #43 by equity capitalization ($45.33B). Within this direct 5-issuer industry benchmark cohort, INCY leads on earnings valuation at 18.4x trailing P/E, while INCY leads on capital efficiency and profitability with 42.4% ROIC and 92.8% gross margin. INCY currently holds the highest overall quantitative score in the immediate peer group at 84/100 (A-) compared with IQV at 64/100 (C).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
IQV ACTIVE IQVIA Holdings Inc.	C	64/100	33.3x	—	9.4%	-2.81%	$45.33B	Benchmark Subject
INCY Incyte Corp.	A-	84/100	18.4x	92.8%	42.4%	+3.07%	$23.68B	/incy-vs-iqv →
MEDP Medpace Holdings Inc.	B+	80/100	42.0x	—	27.9%	-3.77%	$18.95B	/medp-vs-iqv →
CRL Charles River Laboratories International Inc.	C	63/100	—	—	0.4%	-4.44%	$17.95B	/crl-vs-iqv →
ICLR ICON plc	B-	71/100	71.9x	—	3.1%	-1.91%	$16.50B	/iclr-vs-iqv →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001478242

In its most recent audited fiscal period (FY2025, filed 2025-12-31), IQVIA Holdings Inc. (IQV) reported GAAP revenue of $16.31B (+5.9% vs. FY2024 revenue of $15.40B , and +8.8% cumulative change since FY2023) , GAAP net income of $1.36B, operating cash flow of $2.65B, and free cash flow of $1.92B (-5.1% YoY). On the balance sheet, IQV closed FY2025 with $29.94B in total assets against $13.88B in total debt (Altman Z-Score: 2.22, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$16.31B	$1.36B	$2.65B	$1.92B	$29.94B	$13.88B
FY2024 (FY)	2024-12-31	$15.40B	$1.37B	$2.72B	$2.02B	$26.90B	$12.84B
FY2023 (FY)	2023-12-31	$14.98B	$1.36B	$2.15B	$1.47B	$24.93B	$5.83B

3. IQV Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IQV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does IQV compare to INCY and MEDP in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for IQV?

Where is IQV trading relative to its 50-day, 200-day, and 52-week technical levels?

IQV last traded at $267.33 (-2.81% on volume of 1,150,295 shares), positioning the stock +0.24% above its 50-day simple moving average ($266.69) and +27.38% above its 200-day simple moving average ($209.87). Across its 52-week range of $154.50 to $284.50, IQV sits at the 86.8% percentile with a 14-day RSI of 55.7 (BULLISH MOMENTUM) and an implied next-earnings move of ±6.8% ($249.15 to $285.51).

IQV Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does IQV pay a dividend and is it safe?

IQVIA Holdings Inc. (IQV) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: IQV RQD Cockpit IQV 12M Forecast IQV Earnings & Move IQV Dividends & DRIP IQV Insiders & 13F IQV Whale Options IQV Profit Sankey IQV News & Why

Sector Peer Dials

Medpace Holdings Inc.

80 /100

CRL C

Charles River Laboratories International Inc.

IQV Core Snapshot

Market Cap $45.33B

Trailing / Fwd P/E 33.3x / 31.0x

Gross Profit Margin —

Return on Capital (ROIC) 9.4%

Free Cash Flow Yield 4.24%

12M Base Price Target $274.55

FREE TRADER TOOLS

Own IQV Alongside Other Stocks? Run a 30-Second Crash X-Ray

Drop 3–5 tickers into our live Portfolio X-Ray to spot hidden accounting time-bombs and see your composite RQD dial.

⚡ X-Ray My Portfolio With IQV → 🏆 Trade IQV in $100K Prop Arena →

IQV Wire

Why It Moved →

Direct Company Event Yahoo! Finance Canada • 6h ago

IQVIA Holdings Inc. (IQV) Stock Price, News, Quote & History

Direct Company Event ChartMill • 9h ago

IQVIA HOLDINGS INC (NYSE:IQV) Sets Up for Breakout With Strong Technical Ratings

Direct Company Event marketscreener.com • 12h ago

Iqvia Holdings Inc. Stock (IQV) - Quote NYSE

Direct Company Event StockInvest.us • 15h ago

Iqvia Holdings Stock Price Forecast. Should You Buy IQV?

Direct Company Event Seeking Alpha • 18h ago

IQVIA gains as R&D Solutions drive Q3 beat

ROARABLE RATING BRIEF • RQD 64/100 (C) ✓ STAGE-C NUMBER FIREWALL VERIFIED

IQV — IQVIA Holdings Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:11:27Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, IQV scores 64 out of 100, a letter grade of C, with the verdict "Roarable Hold — Fair / Balanced Risk-Reward." Across its five pillars: the Fundamental Cash Engine scores 13 of 20 (ROIC 9.4%; FCF yield 4.24%), suggesting cash generation that is adequate but not exceptional relative to the capital employed. Whale/13F Flow scores 18 of 20 (institutional accumulation and options positioning), the strongest pillar and a supportive signal for near-term demand. Insider Conviction scores 13 of 20 (SEC Form 4 and Congressional PTR cluster flow), a moderate reading. Macro Regime Fit scores 10 of 20 (Beta 1.16; sector sensitivity), indicating above-market sensitivity to broad moves. Forensic Balance Sheet scores 10 of 20 (Altman Z 2.22; Piotroski F 6/9; Debt/Equity 2.14), flagging leverage as the key constraint on the rating.

For a prospective investor, the picture is mixed: institutional positioning is a clear upside driver, while valuation (P/E TTM 33.3, EV/EBITDA 20.4) and elevated leverage limit margin for error. The rating frames the stock as balanced rather than compelling on fundamentals alone.

Snapshot

Price	Market Cap	P/E (TTM)	Forward P/E	EV/EBITDA	EPS (TTM)	Dividend Yield	Beta	52-Wk Range	ROIC %
275.06	$45.33B	33.3	31	20.4	8.25	0%	1.16	$154.5 - $284.5	9.4%

Business

IQVIA Holdings Inc. is a NYSE-listed issuer in the Health Care sector, within the Biotechnology: Commercial Physical & Biological Resarch industry. Per the profile, the company carries a market capitalization of $45.3B. Source data does not describe its specific products, customers, or revenue mechanics beyond sector and industry classification.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$16310.0M	$2182.0M	$1360.0M	N/A	$1920.0M	$1980.0M	$13884.0M
FY 2024	$15405.0M	$2202.0M	$1373.0M	N/A	$2022.8M	$1702.0M	$12838.0M
FY 2023	$14984.0M	$1977.0M	$1358.0M	N/A	$1474.7M	N/A	$5834.0M

Revenue rose from $14984.0M (FY 2023) to $16310.0M (FY 2025), while net income was broadly flat across the three periods. Per the market data, the operating margin is 13.4%, the net margin 8.3%, and ROIC 9.4%. The Forensic Balance Sheet pillar cites an Altman Z-Score of 2.22 and a Piotroski F-Score of 6/9. Reported debt climbed from $5834.0M (FY 2023) to $13884.0M (FY 2025), and the source cites a Debt/Equity of 2.14.

Recent Catalysts & News Wire Analysis

A "CATALYST"-tagged item (GREEN light) cites a Seeking Alpha headline: "IQVIA gains as R&D Solutions drive Q3 beat," the only non-yellow signal in the feed.
A ChartMill item (YELLOW) references strong technical ratings and a possible breakout setup.
A GuruFocus item (YELLOW) notes the stock was up 3.5% but that GF Value indicates overvaluation.
Other wire items (Yahoo! Finance Canada, marketscreener.com, StockInvest.us) are general market-action and quote coverage.
Per the market data, the stock closed at 275.06, down 1.43% on volume of 1,430,079.
Butterfly Supply-Chain Graph: Not available in source data for supply-chain links; no butterfly links or proprietary signals are provided.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

The Butterfly Supply-Chain Graph lists supply chain as "NONE" with no butterfly links. Not available in source data for upstream or downstream dependencies, sector correlations, or second-order bottlenecks beyond the stated sector (Health Care) and industry classification.

Open Questions

What specific products, customers, and revenue segments drive the reported revenue of $16310.0M?
What explains the rise in reported debt from $5834.0M (FY 2023) to $13884.0M (FY 2025), and what are the maturity and interest terms?
Why is EPS reported as N/A across all periods, and what is the reconciled per-share earnings history?
What are the specific institutional and insider transactions underlying the Whale/13F and Insider Conviction pillar scores?
What supply-chain dependencies and sector correlations apply, given the Butterfly graph is empty?

IQV Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for IQVIA Holdings Inc. (IQV) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to IQV Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo! Finance Canada • 6h ago

IQVIA Holdings Inc. (IQV) Stock Price, News, Quote & History

Yahoo! Finance Canada report covering IQVIA Holdings Inc. (IQV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ChartMill • 9h ago

IQVIA HOLDINGS INC (NYSE:IQV) Sets Up for Breakout With Strong Technical Ratings

ChartMill report covering IQVIA Holdings Inc. (IQV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE marketscreener.com • 12h ago

Iqvia Holdings Inc. Stock (IQV) - Quote NYSE

marketscreener.com report covering IQVIA Holdings Inc. (IQV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE StockInvest.us • 15h ago

Iqvia Holdings Stock Price Forecast. Should You Buy IQV?

StockInvest.us report covering IQVIA Holdings Inc. (IQV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Seeking Alpha • 18h ago

IQVIA gains as R&D Solutions drive Q3 beat

Seeking Alpha report covering IQVIA Holdings Inc. (IQV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE GuruFocus • 21h ago

IQVIA Holdings Inc (IQV) Stock Up 3.5% but GF Value Says Overval

GuruFocus report covering IQVIA Holdings Inc. (IQV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

IQVIA Holdings (IQV) Earnings Expected to Grow: Should You Buy?

Yahoo Finance report covering IQVIA Holdings Inc. (IQV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

IQVIA (IQV) Stock Could Be Undervalued Following Its 55% Run

Simply Wall St report covering IQVIA Holdings Inc. (IQV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

IQV Bull vs. Bear Conversation Board — What's Your Call at $267.33?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON IQV 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $297.06 (+8.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is IQV (C • RQD 64/100) a Buy at $275.06?

Welcome to the IQV (IQVIA Holdings Inc.) Roar Pit. Current RQD Composite is 64/100 (Roarable Hold — Fair / Balanced Risk-Reward) in Biotechnology: Commercial Physical & Biological Resarch. Bulls point to operating leverage and sector positioning, while bears focus on valuation multiple compression (33.3x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $214.55 (-22.0%)

Spot @ $275.06

Pump the brakes on IQV — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on IQV, but look at what you are paying: 33.3x trailing P/E with tightening sector spreads. Unless IQVIA Holdings Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

AL AlphaFlow_Cap Verified K Arena Trader 🐂 BULLISH 🎯 Target: $330.07 (+20.0%)

Spot @ $275.06

IQV cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on IQV, the market is fixating on short-term headline noise in Biotechnology: Commercial Physical & Biological Resarch and ignoring the balance sheet and cash flow trajectory. At $275.06 (52-wk range $154.50 - $284.50), any beat on forward guidance forces shorts and underweight funds to chase.